Loading cancer entity…
Loading cancer entity…
Clinical trials
4,036 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (701)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02038777 | A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies | completed | Phase 1 | 48 | PfizerINDUSTRY | 1 | Feb 26, 2025 | clinicaltrials |
| NCT04242849 | IDH1/2 Mutational Analysis in AML Patients: Diagnosis and Follow-up | completed | — | 354 | Josep Carreras Leukaemia Research InstituteOTHER | 0 | Feb 21, 2025 | clinicaltrials |
| NCT03839446 |
| Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy |
| completed |
| Phase 2 |
| 16 |
| Robert Redner, MDOTHER |
| 1 |
| Feb 20, 2025 |
| clinicaltrials |
| NCT00390793 | Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. | completed | Phase 2 | 107 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT04281498 | Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation | completed | Phase 2 | 6 | John MascarenhasOTHER | 2 | Feb 4, 2025 | clinicaltrials |
| NCT03027102 | Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia | completed | Phase 1 | 7 | University Health Network, TorontoOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT06469138 | A Study to Investigate 14C-bemcentinib in Healthy Male Subjects(8479217) | completed | Phase 1 | 6 | BerGenBio ASAINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06790680 | GITMO AML/MDS-Relapse Registry Study | completed | — | 859 | Gruppo Italiano Trapianto di Midollo OsseoOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT03154190 | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer | completed | N/A | 128 | Stanford UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT01261312 | SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) | completed | Phase 1 / Phase 2 | 414 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Jan 23, 2025 | clinicaltrials |
| NCT02997202 | A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) | completed | Phase 3 | 356 | Astellas Pharma Global Development, Inc.INDUSTRY | 16 | Jan 17, 2025 | clinicaltrials |
| NCT03092674 | Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 2 / Phase 3 | 76 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2025 | clinicaltrials |
| NCT02268253 | Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) | completed | Phase 1 / Phase 2 | 82 | Stemline Therapeutics, Inc.INDUSTRY | 2 | Jan 6, 2025 | clinicaltrials |
| NCT03869476 | Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.(BioScoreSMP) | completed | N/A | 133 | University Hospital, AngersOTHER_GOV | 1 | Dec 30, 2024 | clinicaltrials |
| NCT03194685 | Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 97 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT02488408 | A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS | completed | Phase 1 / Phase 2 | 122 | BerGenBio ASAINDUSTRY | 4 | Dec 19, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT00965224 | Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma | completed | Phase 2 | 38 | Zwi BernemanOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT02085408 | Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 3 | 727 | ECOG-ACRIN Cancer Research GroupNETWORK | 3 | Dec 13, 2024 | clinicaltrials |
| NCT02807558 | A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | 155 | Syros PharmaceuticalsINDUSTRY | 2 | Dec 13, 2024 | clinicaltrials |
| NCT00452023 | Pegasys® in Patients With Myeloproliferative Diseases | completed | Phase 2 | 83 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT02014558 | Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 265 | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Dec 3, 2024 | clinicaltrials |
| NCT03730012 | A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 11 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06709235 | Assessing Refractoriness and Infectious Survival Events in AML(ARISE-AML) | completed | — | 280 | Hospices Civils de LyonOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT02927262 | A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission | completed | Phase 2 | 98 | Astellas Pharma Global Development, Inc.INDUSTRY | 21 | Nov 26, 2024 | clinicaltrials |
| NCT04079296 | A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS) | completed | Phase 1 / Phase 2 | 43 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Nov 26, 2024 | clinicaltrials |
| NCT01266083 | WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) | completed | Phase 2 | 22 | Sellas Life Sciences GroupINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT02561455 | Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial | completed | Phase 1 / Phase 2 | 9 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03761914 | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | completed | Phase 1 / Phase 2 | 26 | Sellas Life Sciences GroupINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06692803 | Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy(ABL-2022-03) | completed | — | 2,043 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05659992 | Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06002490 | A Study to Evaluate P1101 in Japanese PV Patients | completed | Phase 3 | 21 | PharmaEssentia Japan K.K.INDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT04253314 | A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation(INNOVATE) | completed | — | 51 | AbbVieINDUSTRY | 1 | Nov 7, 2024 | clinicaltrials |
| NCT02181660 | Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 24 | Astellas Pharma IncINDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT05260203 | MargheRITA (Remote Intelligence for Therapeutic Adherence)(MargheRITA) | completed | N/A | 124 | Advice Pharma Group srlINDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT02236013 | A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 1 | 80 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 5, 2024 | clinicaltrials |
| NCT03047083 | Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review | completed | — | 1,027 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 5, 2024 | clinicaltrials |
| NCT03238248 | Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors | completed | Phase 2 | 71 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT04207190 | Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT04992949 | Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm(CPX-351 TA-SMP) | completed | Phase 2 | 42 | French Innovative Leukemia OrganisationOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT03955783 | Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies | completed | Phase 1 | 78 | Sanjay MohanOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT02532231 | Nivolumab in AML in Remission at High Risk for Relapse | completed | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT04714372 | FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia | completed | Phase 1 | 9 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT00285259 | Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) | completed | Phase 2 | 112 | Astellas Pharma IncINDUSTRY | 1 | Oct 21, 2024 | clinicaltrials |
| NCT03941769 | 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II | completed | Phase 1 / Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04151706 | CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML | completed | Phase 2 | 7 | Robert LowskyOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06369662 | CD155 Expression in Acute Myeloid Leukemia | completed | — | 93 | Assiut UniversityOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT04943757 | Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies(PTBCy) | completed | Phase 2 | 50 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03441048 | Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia | completed | Phase 1 | 26 | Medical College of WisconsinOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT02926586 | Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML | completed | Phase 4 | 68 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 26, 2025source: clinicaltrials